OBJECTIVE: To compare the effectiveness, safety and costs of standard versus individually tailored reduced doses of anti-tumour necrosis factor (TNF) drugs in patients with ankylosing spondylitis (AS) after achieving low-disease activity. METHODS: This was a single-centre prospective observational study performed within the ATTRA registry. The anti-TNF dose tapering strategy was chosen by treating physicians, without prespecified protocol. We used propensity score (PS) methodology to identify two cohorts of patients matched for relevant baseline characteristics who were treated with either reduced (n=53) or standard (n=83) doses of TNF inhibitors. One-year outcomes and costs of anti-TNF drugs were compared between both PS-matched cohorts. RESULTS: In the reduced dosing group, the median dose of TNF inhibitor corresponded to 0.67 and 0.5 of the standard dose initially and at 12 months respectively, and 21% of patients required return to standard dosing regimen. The mean change per year in Bath Ankylosing Spondylitis Activity Index, C-reactive protein , Health Assessment Questionnaire Disability Index and Bath AS functional index, as well as quality-adjusted life-year area under the curve were no different between both groups. The HR (95% CI) of reduced versus standard dosing group for relapse and any adverse event was 1.46 (0.66 to 3.19) and 0.56 (0.22 to 1.44), respectively. Mean difference (95% CI) in cost of anti-TNF drugs was €-4214 (-4707 to -3701) per year of treatment in favour of reduced dosing strategy. CONCLUSIONS: In patients with AS after reaching low-disease activity, a tailored approach to reduce doses of anti-TNF drugs produced similar clinical outcomes at 1 year, but was substantially less costly.

Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic

Institute of Rheumatology and 1st Faculty of Medicine Charles University Prague Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc16021067

003      

CZ-PrNML

005      

20200206074417.0

007      

ta

008      

160722s2016 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1136/annrheumdis-2014-205202 $2 doi

024    7_

$a 10.1136/annrheumdis-2014-205202 $2 doi

035    __

$a (PubMed)25165033

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Závada, Jakub $u Institute of Rheumatology and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

245    12

$a A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study / $c J. Závada, M. Uher, K. Sisol, Š. Forejtová, K. Jarošová, H. Mann, J. Vencovský, K. Pavelka,

520    9_

$a OBJECTIVE: To compare the effectiveness, safety and costs of standard versus individually tailored reduced doses of anti-tumour necrosis factor (TNF) drugs in patients with ankylosing spondylitis (AS) after achieving low-disease activity. METHODS: This was a single-centre prospective observational study performed within the ATTRA registry. The anti-TNF dose tapering strategy was chosen by treating physicians, without prespecified protocol. We used propensity score (PS) methodology to identify two cohorts of patients matched for relevant baseline characteristics who were treated with either reduced (n=53) or standard (n=83) doses of TNF inhibitors. One-year outcomes and costs of anti-TNF drugs were compared between both PS-matched cohorts. RESULTS: In the reduced dosing group, the median dose of TNF inhibitor corresponded to 0.67 and 0.5 of the standard dose initially and at 12 months respectively, and 21% of patients required return to standard dosing regimen. The mean change per year in Bath Ankylosing Spondylitis Activity Index, C-reactive protein , Health Assessment Questionnaire Disability Index and Bath AS functional index, as well as quality-adjusted life-year area under the curve were no different between both groups. The HR (95% CI) of reduced versus standard dosing group for relapse and any adverse event was 1.46 (0.66 to 3.19) and 0.56 (0.22 to 1.44), respectively. Mean difference (95% CI) in cost of anti-TNF drugs was €-4214 (-4707 to -3701) per year of treatment in favour of reduced dosing strategy. CONCLUSIONS: In patients with AS after reaching low-disease activity, a tailored approach to reduce doses of anti-TNF drugs produced similar clinical outcomes at 1 year, but was substantially less costly.

650    _2

$a adalimumab $x aplikace a dávkování $x ekonomika $7 D000068879

650    _2

$a dospělí $7 D000328

650    _2

$a antirevmatika $x aplikace a dávkování $x ekonomika $7 D018501

650    _2

$a plocha pod křivkou $7 D019540

650    _2

$a C-reaktivní protein $x metabolismus $7 D002097

650    _2

$a posuzování pracovní neschopnosti $7 D004185

650    _2

$a přežití po terapii bez příznaků nemoci $7 D018572

650    _2

$a náklady na léky $7 D016527

650    _2

$a etanercept $x aplikace a dávkování $x ekonomika $7 D000068800

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    _2

$a lidé $7 D006801

650    _2

$a infliximab $x aplikace a dávkování $x ekonomika $7 D000069285

650    _2

$a udržovací chemoterapie $x ekonomika $7 D060046

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a tendenční skóre $7 D057216

650    _2

$a prospektivní studie $7 D011446

650    _2

$a kvalitativně upravené roky života $7 D019057

650    _2

$a recidiva $7 D012008

650    _2

$a stupeň závažnosti nemoci $7 D012720

650    _2

$a ankylózující spondylitida $x farmakoterapie $x ekonomika $7 D013167

650    _2

$a časové faktory $7 D013997

650    _2

$a TNF-alfa $x antagonisté a inhibitory $7 D014409

651    _2

$a Česká republika $7 D018153

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a pozorovací studie $7 D064888

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Uher, Michal $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.

700    1_

$a Sisol, Katarína $u Institute of Rheumatology and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Forejtová, Šárka $u Institute of Rheumatology and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Jarošová, Kateřina $u Institute of Rheumatology and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Mann, Heřman, $d 1973- $7 nlk20010095506 $u Institute of Rheumatology and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Vencovský, Jiří $u Institute of Rheumatology and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Pavelka, Karel $u Institute of Rheumatology and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

773    0_

$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 75, č. 1 (2016), s. 96-102

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25165033 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160722 $b ABA008

991    __

$a 20200206074805 $b ABA008

999    __

$a ok $b bmc $g 1155737 $s 945595

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2016 $b 75 $c 1 $d 96-102 $e 20140827 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444

LZP    __

$a Pubmed-20160722